• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Disc Medicine Inc.

    6/20/24 4:01:56 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRON alert in real time by email
    SC 13D/A 1 d849009dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Disc Medicine, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    254604101

    (CUSIP Number)

     

    Alejandro Moreno

    Langhorne S. Perrow c/o

    Access Industries, Inc.

    40 West 57th Street, 28th Floor

    New York, New York 10019

    (212) 247-6400

    with copies to:

    Nicholas P. Pellicani

    Debevoise & Plimpton LLP

    65 Gresham Street

    EC2V 7NQ

    London

    + 44 20 7786 9000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 17, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

     

     

     


    CUSIP No. 254604101

     

     1   

     NAME OF REPORTING PERSON.

     

     AI DMI LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC, AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     3,762,507 shares(1)

        8  

     SHARED VOTING POWER

     

     0 shares

        9  

     SOLE DISPOSITIVE POWER

     

     3,762,507 shares(1)

       10  

     SHARED DISPOSITIVE POWER

     

     0 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,762,507 shares(1)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     12.6%(2)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)

     

    (1)

    Represents (i) 3,558,426 shares of Common Stock and (ii) 204,081 pre-funded warrants to purchase shares of Common Stock at $0.0001 per share (the “Pre-Funded Warrants”).

    (2)

    Based on 29,843,966 shares of Common Stock consisting of (i) 29,639,885 shares of Common Stock outstanding immediately following the Issuer’s registered offering of 4,944,000 shares of Common Stock (the “Offering”), as reported in the Issuer’s Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the “SEC”) on June 14, 2024, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CUSIP No. 254604101

     

     1   

     NAME OF REPORTING PERSON.

     

     Access Industries Holdings LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC, AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     3,762,507 shares(1)

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     3,762,507 shares(1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,762,507 shares(1)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     12.6%(2)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)

     

    (1)

    Represents (i) 3,558,426 shares of Common Stock and (ii) 204,081 Pre-Funded Warrants.

    (2)

    Based on 29,843,966 shares of Common Stock consisting of (i) 29,639,885 shares of Common Stock outstanding immediately following the Offering, as reported in the Issuer’s Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on June 14, 2024, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CUSIP No. 254604101

     

     1   

     NAME OF REPORTING PERSON.

     

     Access Industries Management, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC, AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     State of Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     3,762,507 shares(1)

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     3,762,507 shares(1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,762,507 shares(1)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     12.6%(2)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)

     

    (1)

    Represents (i) 3,558,426 shares of Common Stock and (ii) 204,081 Pre-Funded Warrants.

    (2)

    Based on 29,843,966 shares of Common Stock consisting of (i) 29,639,885 shares of Common Stock outstanding immediately following the Offering, as reported in the Issuer’s Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on June 14, 2024, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CUSIP No. 254604101

     

     1   

     NAME OF REPORTING PERSON.

     

     Len Blavatnik

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC, AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     3,762,507 shares(1)

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     3,762,507 shares(1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,762,507 shares(1)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     12.6%(2)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    Represents (i) 3,558,426 shares of Common Stock and (ii) 204,081 Pre-Funded Warrants.

    (2)

    Based on 29,843,966 shares of Common Stock consisting of (i) 29,639,885 shares of Common Stock outstanding immediately following the Offering, as reported in the Issuer’s Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on June 14, 2024, and (ii) 204,081 shares of Common Stock underlying the Pre-Funded Warrants.


    CONTINUATION PAGES TO AMENDMENT NO. 4 TO SCHEDULE 13D

    This Amendment No. 4 to Schedule 13D is being filed by AI DMI LLC (“AI DMI”), Access Industries Holdings LLC (“AIH”), Access Industries Management, LLC (“AIM”) and Len Blavatnik (collectively, the “Reporting Persons”, and each, a “Reporting Person”), in respect of the common stock, par value $0.0001 per share (the “Common Stock”), of Disc Medicine, Inc. (the “Issuer”). The shares of Common Stock of the Issuer are listed on the Nasdaq Global Market under the symbol “IRON.”

    The Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on January 9, 2023, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on February 17, 2023, Amendment No. 2 to the Schedule 13D filed by the Reporting Persons with the SEC on June 20, 2023 and Amendment No. 3 to the Schedule 13D filed by the Reporting Persons on November 13, 2023 (together, the “Schedule”), is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 4. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

     

    Item 3

    Source and Amount of Funds and Other Consideration.

    The disclosure in Item 3 to the Schedule is hereby supplemented by adding the following at the end thereof:

    On June 17, 2024, AI DMI purchased 416,667 shares of Common Stock at a purchase price of $36.00 per share of Common Stock pursuant to the prospectus filed with the SEC on June 14, 2024 pursuant to Rule 424(b)(5) in a registered offering. AI DMI funded the purchase of shares of Common Stock using capital contributed from affiliated entities, which funded that capital using cash on hand.

     

    Item 5

    Interest in Securities of the Issuer

    Item 5 to the Schedule is hereby amended and restated as follows:

    (a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including but not limited to footnotes to such information) are incorporated herein by reference.

    The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of shares of Common Stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

    3,558,426 shares of Common Stock and 204,081 Pre-Funded Warrants are owned directly by AI DMI and may be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH and (iii) AIH indirectly controls all of the outstanding voting interests in AI DMI. Each of the Reporting Persons (other than AI DMI), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

    (c) The following transactions in the Issuer’s securities have been effected by Reporting Persons within the 60 days prior to this filing: The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference.

    (d) Not applicable.

    (e) Not applicable.


    Item 7

    Materials to Be Filed as Exhibits

    The disclosure in Item 7 is hereby supplemented by adding the following in appropriate numerical order:

     

    Exhibit    Description
    99.11    Joint Filing Agreement, dated as of June 20, 2024.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: June 20, 2024

     

    AI DMI LLC       By: Access Industries Management, LLC, its Manager
         

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Title: Executive Vice President
    ACCESS INDUSTRIES HOLDINGS LLC       By: Access Industries Management, LLC, its Manager
         

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Title: Executive Vice President
    ACCESS INDUSTRIES MANAGEMENT, LLC      

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Title: Executive Vice President
         

    /s/ *

          Name: Leonard Blavatnik

     

    *

    The undersigned, by signing his name hereto, executes this Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

     

    By:   /s/ Alejandro Moreno
      Name: Alejandro Moreno
      Attorney-in-Fact
    Get the next $IRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRON

    DatePrice TargetRatingAnalyst
    6/11/2025$89.00Strong Buy
    Raymond James
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    8/22/2024$75.00Overweight
    Wells Fargo
    4/1/2024$40.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

      Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

      6/12/25 7:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine to Participate in Upcoming Investor Conferences

      WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5th at 10:30 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th at 1:20 p.m. ET. Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and

      5/28/25 4:01:00 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

      Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

      5/14/25 9:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on Disc Medicine with a new price target

      Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00

      6/11/25 7:53:18 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Disc Medicine

      TD Cowen initiated coverage of Disc Medicine with a rating of Buy

      2/27/25 6:22:05 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Disc Medicine from Equal-Weight to Overweight and set a new price target of $85.00

      11/5/24 7:18:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      11/14/24 5:44:55 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      11/14/24 4:33:10 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Disc Medicine Inc.

      SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

      11/8/24 10:52:39 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

      Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

      11/12/24 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

      WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

      10/23/24 8:00:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

      WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo

      9/19/24 8:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 8:00:05 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 5:27:54 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/20/24 5:19:39 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Financials

    Live finance-specific insights

    See more
    • Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

      Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

      6/12/25 7:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

      Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

      5/14/25 9:30:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

      Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

      1/21/25 7:45:00 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director White William Richard

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/13/25 5:32:13 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ratcliffe Liam

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/13/25 5:29:57 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nicholson Donald William

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      6/13/25 5:25:45 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRON
    SEC Filings

    See more
    • Disc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      6/13/25 5:05:09 PM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Disc Medicine Inc.

      SCHEDULE 13G - Disc Medicine, Inc. (0001816736) (Subject)

      5/12/25 10:44:44 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Disc Medicine Inc.

      SCHEDULE 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      5/12/25 10:28:12 AM ET
      $IRON
      Biotechnology: Pharmaceutical Preparations
      Health Care